Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). RaQualia Pharma's share price for the quarter that ended in Mar. 2026 was 円778. RaQualia Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 26 Mil. Therefore, RaQualia Pharma's market cap for the quarter that ended in Mar. 2026 was 円20,242 Mil.
RaQualia Pharma's quarterly market cap
increased
from Sep. 2025 (円14,038 Mil) to Dec. 2025 (円24,703 Mil) but then
declined
from Dec. 2025 (円24,703 Mil) to Mar. 2026 (円20,242 Mil).
RaQualia Pharma's annual market cap
declined
from Dec. 2023 (円14,877 Mil) to Dec. 2024 (円8,386 Mil) but then
increased
from Dec. 2024 (円8,386 Mil) to Dec. 2025 (円24,703 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. RaQualia Pharma's Enterprise Value for Today is 円12,995 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
RaQualia Pharma Market Cap Related Terms
RaQualia Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, RaQualia Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
RaQualia Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Market Cap of 円14,700 Mil as of Aug. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #767 out of 1422 companies in the Biotechnology industry, placing it in the top 53.9%.
Is RaQualia Pharma's Market Cap too high?
RaQualia Pharma's current Market Cap is 円14,700 Mil. Based on the distribution chart, RaQualia Pharma ranks #767 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #767 out of 1422 companies for Market Cap. This places RaQualia Pharma in the lower half of its industry. The industry median Market Cap is 122.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.48, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 122.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Market Cap is 円14,700 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円908.80, compared to a current price of 円565.00 — trading 37.8% below its estimated fair value. The current Market Cap is 円14,700 Mil. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Market Cap is 円14,700 Mil as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円565.00 is trading 37.8% below its estimated GF Value™ of 円908.80.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Market Cap: 円14,700 Mil
GF Value™: 円908.80 vs. price of 円565.00 (37.8% below fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
